Literature DB >> 11849310

IgG4 breaking the rules.

Rob C Aalberse1, Janine Schuurman.   

Abstract

Immunoglobulin G4 (IgG4) antibodies have been known for some time to be functionally monovalent. Recently, the structural basis for this monovalency has been elucidated: the in vivo exchange of IgG half-molecules (one H-plus one L-chain) among IgG4. This process results in bispecific antibodies that in most situations will behave as functionally monovalent antibodies. The structural basis for the abnormal behaviour of IgG4 seems to be largely the result of a single amino acid change relative to human IgG1: the change of a proline in core hinge of IgG1 to serine. This results in a marked shift in the equilibrium between interchain disulphide bridges and intrachain disulphide bridges, which for IgG4 results in 25-75% absence of a covalent interaction between the H-chains. Because of strong non-covalent interactions between the CH3 domains (and possibly also between the CH1 domain and the trans-CH2 domain) IgG4 is a stable four-chain molecule and does not easily exchange half-molecules under standard physiological conditions in vitro. We postulate that the exchange is catalysed in vivo by protein disulphide isomerase (PDI) and/or FcRn (the major histocompatibility complex (MHC)-related Fc receptor) during transit of IgG4 in the endosomal pathway in endothelial cells. Because IgG4 is predominantly expressed under conditions of chronic antigen exposure, the biological relevance of this exchange of half-molecules is that it generates antibodies that are unable to form large immune complexes and therefore have a low potential for inducing immune inflammation. In contrast to monovalent immunoglobulin fragments, these scrambled immunoglobulins have a normal half-life. The significance of the ensuing bispecificity needs further evaluation, because this will be relevant only in situations where high IgG4 responses are found to two unrelated antigens that happen to be present in the body at the same time and place. In this context the significance of IgG4 autoreactivity might have to be re-evaluated. The main function of IgG4, however, is presumably to interfere with immune inflammation induced by complement-fixing antibodies, or, in the case of helminth infection or allergy, by IgE antibodies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11849310      PMCID: PMC1782638          DOI: 10.1046/j.0019-2805.2001.01341.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  62 in total

Review 1.  IgE-mediated antigen presentation.

Authors:  G C Mudde; R Bheekha; C A Bruijnzeel-Koomen
Journal:  Allergy       Date:  1995-03       Impact factor: 13.146

Review 2.  Measurement of specific and nonspecific IgG4 levels as diagnostic and prognostic tests for clinical allergy. AAAI Board of Directors.

Authors: 
Journal:  J Allergy Clin Immunol       Date:  1995-03       Impact factor: 10.793

3.  Protein structure comparison by alignment of distance matrices.

Authors:  L Holm; C Sander
Journal:  J Mol Biol       Date:  1993-09-05       Impact factor: 5.469

Review 4.  Anatomy of the antibody molecule.

Authors:  E A Padlan
Journal:  Mol Immunol       Date:  1994-02       Impact factor: 4.407

Review 5.  Allergen-specific IgG4 in atopic disease.

Authors:  R C Aalberse; F Van Milligen; K Y Tan; S O Stapel
Journal:  Allergy       Date:  1993-11       Impact factor: 13.146

6.  Practice parameters for allergy diagnostic testing. Joint Task Force on Practice Parameters for the Diagnosis and Treatment of Asthma. The American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology.

Authors:  I L Bernstein; W W Storms
Journal:  Ann Allergy Asthma Immunol       Date:  1995-12       Impact factor: 6.347

7.  Differential expression of IgE and IgG4 specific antibody responses in asymptomatic and chronic human filariasis.

Authors:  A Kurniawan; M Yazdanbakhsh; R van Ree; R Aalberse; M E Selkirk; F Partono; R M Maizels
Journal:  J Immunol       Date:  1993-05-01       Impact factor: 5.422

8.  Human/mouse chimeric monoclonal antibodies with human IgG1, IgG2, IgG3 and IgG4 constant domains: electron microscopic and hydrodynamic characterization.

Authors:  M L Phillips; M H Tao; S L Morrison; V N Schumaker
Journal:  Mol Immunol       Date:  1994-10       Impact factor: 4.407

9.  Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.

Authors:  D Colcher; D Milenic; M Roselli; A Raubitschek; G Yarranton; D King; J Adair; N Whittle; M Bodmer; J Schlom
Journal:  Cancer Res       Date:  1989-04-01       Impact factor: 12.701

10.  Thiol-proteindisulfide-oxidoreductase (proteindisulfide isomerase): a new plasma membrane constituent of mature human B lymphocytes.

Authors:  H Kröning; T Kähne; A Ittenson; A Franke; S Ansorge
Journal:  Scand J Immunol       Date:  1994-04       Impact factor: 3.487

View more
  135 in total

1.  CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques.

Authors:  Jessica E Taaffe; Steven E Bosinger; Gregory Q Del Prete; James G Else; Sarah Ratcliffe; Christopher D Ward; Thi Migone; Mirko Paiardini; Guido Silvestri
Journal:  J Med Primatol       Date:  2011-11-14       Impact factor: 0.667

2.  Relative stabilities of IgG1 and IgG4 Fab domains: influence of the light-heavy interchain disulfide bond architecture.

Authors:  James T Heads; Ralph Adams; Lena E D'Hooghe; Matt J T Page; David P Humphreys; Andrew G Popplewell; Alastair D Lawson; Alistair J Henry
Journal:  Protein Sci       Date:  2012-08-09       Impact factor: 6.725

Review 3.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

4.  Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines.

Authors:  Christoph Spiess; Jack Bevers; Janet Jackman; Nancy Chiang; Gerald Nakamura; Michael Dillon; Hongbin Liu; Patricia Molina; J Michael Elliott; Whitney Shatz; Justin M Scheer; Glen Giese; Josefine Persson; Yin Zhang; Mark S Dennis; James Giulianotti; Prateek Gupta; Dorothea Reilly; Enzo Palma; Jianyong Wang; Eric Stefanich; Heleen Scheerens; Germaine Fuh; Lawren C Wu
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

5.  Autoimmunity against carbonic anhydrase II affects retinal cell functions in autoimmune retinopathy.

Authors:  Grazyna Adamus; Landon Karren
Journal:  J Autoimmun       Date:  2009-03-06       Impact factor: 7.094

6.  Engineering an improved IgG4 molecule with reduced disulfide bond heterogeneity and increased Fab domain thermal stability.

Authors:  Shirley J Peters; C Mark Smales; Alistair J Henry; Paul E Stephens; Shauna West; David P Humphreys
Journal:  J Biol Chem       Date:  2012-05-18       Impact factor: 5.157

Review 7.  The great mimicker: IgG4-related disease.

Authors:  Rodolfo Perez Alamino; Luis R Espinoza; Arnold H Zea
Journal:  Clin Rheumatol       Date:  2013-07-23       Impact factor: 2.980

Review 8.  Mechanisms and assessment of IgG4-related disease: lessons for the rheumatologist.

Authors:  Motohisa Yamamoto; Hiroki Takahashi; Yasuhisa Shinomura
Journal:  Nat Rev Rheumatol       Date:  2013-12-03       Impact factor: 20.543

9.  Immunogenicity and efficacy of Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice.

Authors:  Robert W Maitta; Kausik Datta; Andrew Lees; Shelley Sims Belouski; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

10.  A novel monoclonal antibody to CD40 prolongs islet allograft survival.

Authors:  M Lowe; I R Badell; P Thompson; B Martin; F Leopardi; E Strobert; A A Price; H S Abdulkerim; R Wang; N N Iwakoshi; A B Adams; A D Kirk; C P Larsen; K A Reimann
Journal:  Am J Transplant       Date:  2012-05-08       Impact factor: 8.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.